Pediatric blood & cancer · 2008
Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report.
Клиническое исследование II фазыСтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Franklin Janet L, Seibel Nita L, Krailo Mark, Fu Cecilia, Adamson Peter C, Reaman Gregory, Children's Oncology Group
Аннотация
BACKGROUND: To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
PROCEDURE: Patients who were under the age of 22-year-old at the time of the original ALL or AML diagnosis and in a second relapse were accrued from August 2002 to May 2005 for this Children's Oncology Group (COG) phase 2 study (ADVL0023). Ten patients with ALL and two patients with AML were enrolled.
RESULTS: There were no complete or partial responses observed. The most common grade 3 or 4 toxicities were hematologic followed by febrile neutropenia. One patient developed a dose limiting elevation in serum bilirubin, but no other significant hepatotoxicity was observed.
CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.
PROCEDURE: Patients who were under the age of 22-year-old at the time of the original ALL or AML diagnosis and in a second relapse were accrued from August 2002 to May 2005 for this Children's Oncology Group (COG) phase 2 study (ADVL0023). Ten patients with ALL and two patients with AML were enrolled.
RESULTS: There were no complete or partial responses observed. The most common grade 3 or 4 toxicities were hematologic followed by febrile neutropenia. One patient developed a dose limiting elevation in serum bilirubin, but no other significant hepatotoxicity was observed.
CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.
Предметные рубрики MeSH
Acute DiseaseAdolescentAdultAntineoplastic Agents, PhytogenicBone Marrow DiseasesChildChild, PreschoolDocetaxelDrug Administration ScheduleFemaleFeverHumansInfantInfusions, IntravenousLeukemiaLeukemia, MyeloidMaleNeutropeniaPrecursor Cell Lymphoblastic Leukemia-LymphomaSalvage TherapyTaxoidsTreatment Failure